Lupin Limited has entered into an exclusive marketing and commercialization agreement with Amman Pharmaceuticals Industries for Ranibizumab, a biosimilar of Lucentis®, in the Middle East region. This includes select territories of Jordan, Saudi Arabia, UAE, Iraq, Lebanon, and other GCC countries.
Lupin and Amman Pharma share a common goal of providing innovative and high-quality healthcare solutions to patients in the MENA region.
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment designed to bind to and inhibit vascular endothelial growth factor A (VEGF-A). Ranibizumab's applications include the treatment of wet AMD, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
“Our aim is to be at the forefront of transforming patient’s lives and building a healthier, brighter future for all. We are excited about the partnership with Amman Pharma to bring Ranibizumab to the MENA region,” said Nilesh Gupta, Managing Director, Lupin.
“We aim to empower patients by offering timely and widespread access to cutting-edge biologic medication at affordable costs. Our successful development of biosimilar Ranibizumab stands as testament to this commitment,” said Dr. Cyrus Karkaria, President Biotechnology, Lupin. “Our mission in collaborating with Amman Pharma is to provide patients with advanced biologics that hold the promise of reshaping their health journey.”
Dr. Fadi Alatrash, General Manager of Amman Pharma said, “We are proud to partner with Lupin, a world-leading biopharmaceutical company, to market and commercialize Ranibizumab. This partnership is aligned with our mission to provide high-quality products and access to advanced biosimilars to patients in the region. It also expands our biosimilar portfolio and strengthens our position in the niche Ophthalmology market.”